Tobias Arkenau

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

May, 2025

Tobias Arkenau

Apr 19, 2025, 08:05 | Blog

Vivek Subbiah: Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies

Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on…

Apr 18, 2025, 19:10 | Science

Rafael Grochot: The safety and activity of FGFR inhibitors in early-phase clinical trials

Rafael Grochot, Medical Oncologist - Clinical Trial Specialist at Sarah Cannon Research Institute, shared a…

Sep 11, 2024, 06:09 | Blog

Vivek Subbiah: First-in human phase 1 dose-escalation study of BT5528 in Patients With Advanced Solid Tumors

Vivek Subbiah shared a post on X: "Hot of the press - Pleased to share our…

Jun 18, 2024, 07:07 | Insight

Tislelizumab plus chemotherapy in advanced gastric/GEJ adenocarcinoma

Erman Akkus, Medical Oncology Fellow at Ankara University, shared on X: "Tislelizumab plus chemotherapy vs…

All: 4 Posts: 1 - 100

'

Who From Oncology is Featured in TIME100 Health 2025?

'

Francesco Acerbi and Testicular Cancer: The Defender's Fight and Triumphant Return to Football

'

Yvonne Award for Breakthrough Research 2024 Recipient to Time100 Health List

'

Dr Saunthari Somasundaram is the new President-Elect of the NCD Alliance

'

Does Plastic Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023